To evaluate the efficacy of topiramate in conjunction with metformin for weight management and metabolic improvement in women with polycystic ovary syndrome (PCOS), focusing on primary outcomes such as weight loss percentage and metabolic markers.
Key Findings:
Participants receiving topiramate plus metformin lost an average of 4.5% of their weight compared to 1.4% in the placebo group, with statistical significance.
Both groups showed improvements in androgen levels, lipid profiles, and psychosocial scores, indicating a holistic benefit of the treatment.
Interpretation:
The combination of topiramate, metformin, and a low-calorie diet is an effective and safe strategy for weight management in women with PCOS, despite some side effects. Individualized treatment plans should be considered based on patient characteristics.
Limitations:
The study's sample size and duration may limit the generalizability of the findings, and potential biases in the study design should be acknowledged.
Long-term safety and efficacy of topiramate in PCOS remain unclear, necessitating further investigation.
Conclusion:
Further research is needed to explore the role of topiramate in PCOS, particularly in tailoring weight management strategies based on individual phenotypes and adiposity distribution, as well as assessing long-term outcomes.
Patients with greater frailty showed larger improvements in health-related quality of life, while cardiovascular treatment effects did not differ significantly across frailty categories.
